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Abstract
Background: Central sensitization is modulated by the endogenous opioid system and plays a major role in the
development and maintenance of pain. Recent animal studies performed following resolution of inflammatory pain
showed reinstatement of tactile hypersensitivity induced by administration of a mu-opioid-antagonist, suggesting
latent sensitization is mediated by endogenous opioids. In a recent crossover study in healthy volunteers, following
resolution of a first-degree burn, 4 out of 12 volunteers developed large secondary areas of hyperalgesia areas after
a naloxone infusion, while no volunteer developed significant secondary hyperalgesia after the placebo infusion. In
order to consistently demonstrate latent sensitization in humans, a pain model inducing deep tissue inflammation,
as used in animal studies, might be necessary. The aim of the present study is to examine whether a high-dose
target-controlled naloxone infusion can reinstate pain and hyperalgesia following recovery from open groin hernia
repair and thus consistently demonstrate opioid-mediated latent sensitization in humans.
Methods/Design: Patients submitted to unilateral, primary, open groin hernia repair will be included in this
randomized, placebo-controlled, double-blind, crossover study. The experimental days take place 6–8 weeks after
surgery, time-points at which patients are expected to be almost pain- free. Prior to administration of naloxone or
placebo, the primary outcome (a summated measure of pain: at rest, during transition from supine to standing
position, and evoked by pressure algometry) and the secondary outcomes (secondary hyperalgesia/allodynia,
pressure pain thresholds, assessed at the surgical site and at the mirror-site in the contralateral groin, and, opioid
withdrawal symptoms) will be assessed. These assessments will be repeated at each step of the target-controlled
infusion of placebo or naloxone at estimated median (95 % CI) plasma concentrations of 344 ng/ml (130;567), 1059
ng/ml (400;1752) and 3196 ng/ml (1205;5276).
Discussion: We aim to demonstrate opioid-mediated latent sensitization in a post-surgical setting, using pain as a
clinical relevant variable. Impairment of the protective endogenous opioid system may play an important role in
the transition from acute to chronic pain. In order to sufficiently block the endogenous opioid system, a high-dose
target-controlled naloxone-infusion is used, in accordance with recent findings in animal studies.
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Background
Central sensitization is a condition in which the central
nervous system is regulated into a state of high reactivity
producing augmented responses. It plays a major role in
the development and maintenance of pain [1, 2] and is
modulated by the endogenous opioid system, which is
known to be impaired or altered in various chronic pain
conditions [2–4]. Mu-opioid-receptor (MOR)-antago-
nists can be used to block the endogenous opioid system
and thereby to study the role of the endogenous opioids
on central processing of pain.
Experimental studies in rodents showed a phenomenon
of long-lasting vulnerability to noxious stimuli mediated
by endogenous opioids, termed latent sensitization [5].
Following resolution of inflammatory pain, administration
of MOR-antagonists led to N-methyl-d-aspartic acid
(NMDA)-receptor dependent reinstatement of hypersen-
sitivity at the injury site [6, 7]. Interestingly, naloxone-
methiodine [6] and naltrexone-methobromide [7], two
peripherally acting opioid antagonists not crossing the
blood-brain barrier, did not change nociceptive thresholds
following resolution of the inflammatory injury, confirming
that latent sensitization is centrally mediated. Furthermore,
intrathecal administration of pertussis toxin, disrupting Gα-
subunit (Gαi/o-proteins), generated reinstatement of mech-
anical hypersensitivity, suggesting tonic activation of
G-protein-coupled receptors [7]. Translational re-
search is needed to study the phenomenon of latent
sensitization and its modulation by the endogenous
opioid system in humans.
Human experimental and clinical pain models [8, 9]
can be used to study central sensitization. One feature of
central sensitization is secondary hyperalgesia, where
sensory stimulation of normal tissue adjacent to an in-
jury is perceived as painful. Secondary hyperalgesia is
thus characterized by expansion of receptive fields of
dorsal horn neurons [1, 2]. The phenomenon of latent
sensitization has not yet been robustly shown in
humans. In a previous study in healthy volunteers,
blockade of the endogenous opioid system by low-dose
naloxone (0.021 mg/kg) did not significantly affect the
magnitude of the areas of secondary hyperalgesia follow-
ing resolution of a first-degree burn-injury [10]. How-
ever, following administration of high-dose naloxone (2
mg/kg), 4 out of 12 volunteers developed large second-
ary areas of hyperalgesia), while no volunteer developed
significant secondary hyperalgesia during a placebo infu-
sion [11]. These findings, though not as robustly shown
as in rodents, suggest that latent sensitization, modu-
lated by the endogenous opioid system, is present in
humans.
The burn-injury model, applied in the human studies
is a validated, tonic thermal injury model, which has
been widely used in pain studies in healthy volunteers
[12, 13]. This model induces, however, only superficial
inflammatory damage, in contrast to the deep tissue in-
flammation induced by plantar incision [6] or by intra-
plantar injection of complete Freund’s adjuvant (CFA)
[7] used in animal studies. A more invasive pain model,
inducing deep tissue inflammation, thus compatible with
the clinical scenario, might be necessary to consistently
generate latent sensitization in humans. We therefore
opted for a post-surgical model in the present study.
Open groin hernia repair (GHR) induces very likely a
higher degree of nociception compared to the burn-
injury model and is associated with long-lasting periph-
eral and central sensitization [14].
We hypothesize that a high-dose naloxone infusion
will reinstate pain (resting pain, dynamic pain and pres-
sure evoked pain) and hyperalgesia 6 to 8 weeks after
primary unilateral, open GHR with mesh implantation.
Although at this time interval patients are expected to
be nearly pain-free, tissue injury induced by surgery
has not yet completely resolved. The endogenous opi-
oid system has a protective function and likely contrib-
utes to the pain-free state and to a more rapid
regaining of function of the affected area [15–17]. Im-
pairment of the endogenous opioid system may be an
important pathophysiological mechanism in persistent
pain, after surgery or trauma. By blocking the endogen-
ous opioid system, using a target-controlled infusion
(TCI) of high-dose naloxone, we expect to observe a
reinstatement of pain evoked by the surgically induced
tissue damage. Noteworthy, in the absence of an injury
it is unlikely that naloxone causes pain, since studies in
healthy volunteers using naloxone doses in the mg/kg
range reported behavioral adverse effects as nausea or
tiredness but, except for epigastralgia, pain has not
been described [18–22].
The primary aim of this study is thus to examine the ef-
fect of a naloxone high-dose TCI (total dose: 3.25 mg/kg)
on pain reinstatement after recovery from GHR.
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Secondary aims are to study the effect of naloxone on
secondary hyperalgesia, allodynia and pressure pain
thresholds (PPT), at the surgical site and at the mirror-
site in the contralateral groin. Opioid withdrawal
symptoms and psychometric variables: i.e., anxiety,




Patients submitted to unilateral, primary open GHR by the
Lichtenstein procedure will be recruited at the Department
of Surgical Gastroenterology at Gentofte/Herlev Hospital.
The investigator will provide participants with oral and
written information about the study and its possible risks.
Informed consent from each participant will be obtained.
Participants will receive a compensation of EUR 20 (USD
27) per hour for their participation in the study. Inclusion
and exclusion criteria are presented in Table 1.
The study protocol has been approved by the local
Ethical Committee (Videnskabsetisk Komité F for Region
Hovedstaden; H-15002712). The study will be conducted
in accordance with the amended Helsinki Declaration.
Setting
The experimental procedures of the study take place
in a quiet examination laboratory (22–25 °C) at the
Departments of Anesthesiology, 4231 and Neuroanesthesia,
3042 Rigshospitalet. Participants will adopt a comfortable
supine position during the assessments.
Study design
This randomized, placebo-controlled, double-blind, cross-
over study consists of an information day prior to the sur-
gery and 2 experimental days. A follow-up phone call will
be performed 2–3 weeks after surgery to assess the
post-surgical pain intensity and signs of post-surgical
complications (swelling, erythema, wound-dehiscence,
fever, malaise, excessive lymph node swelling). The
study drug (naloxone or placebo) is given in a ran-
domized fashion on the examination days, Day 1 and
Day 2. Day 1 takes place 6–8 weeks after surgery and
is separated by 7 days from Day 2 (Fig. 1).
On the information day, participants are orally informed
by the investigator about the study and receive written in-
formation. On Day 1, participants are asked to sign an in-
formed consent, if they meet the inclusion criteria. After a
brief medical examination by a physician, participants are
asked to fill out the Hospital Anxiety and Depression
Scale (HADS) [23, 24] and the Pain Catastrophizing Scale
(PCS) [25]. An instant urine drug screening test
(morphine, methadone, buprenorphine, codeine, tramadol,
ketobemidone, oxycodone, hydromorphone, dextromethor-
phan) is performed in order to avoid severe opioid-
withdrawal reactions during the naloxone-administration. If
a negative test result is obtained, baseline (−20 minutes
to −8 minutes, Fig. 2) pain assessments, as well as assess-
ments of secondary hyperalgesia and PPTs are carried out
followed by administration of placebo or naloxone. As-
sessments will be repeated during infusion of placebo or
naloxone at 3 different, estimated stable plasma concen-
trations (15 minutes to 25 minutes; 39 minutes to 49 mi-
nutes; 65 minutes to 75 minutes; cf. subsection below:
Intervention; Fig. 2). On Day 2 experimental procedures
are identical to Day 1.
Randomization
Randomization will be performed by the Skanderborg
Hospital Pharmacy using a randomization software
(www.random.org). The pharmacy is also responsible for
the packaging and labeling of naloxone (4 mg/ml) and
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Healthy male (ASA I–II) • Participant does not understand
Danish
• 18 ≤ age≤ 65 years • Participant is not cooperative
• Patients submitted to elective,
unilateral, primary, open groin
herniarepair 6–8 weeks prior to
study start
• Participant had previous surgery
in the inguinal region
• Open surgical procedure by the
Lichtenstein method
• Pain at rest > 3 (NRS, 0–10)
• Signed informed consent • Activity-related pain in the surgical
field > 5 (NRS, 0–10)
• 18 kg/m2 < BMI < 30 kg/m2 • Nerve lesions in the assessment
sites (for instance, after trauma,
disc herniation, etc.)






• Skin or nerve lesions or tattoos
in the assessment areas
• Regular use of analgesic drugs
(≥ twice a week)
• Allergy against morphine or other
opioids (including naloxone)
• Alcohol or drug abuse
• Use of psychotropic drugs
(except SSRI)
• Neurological or psychiatric disease
• Chronic pain condition
• Use of prescription drugs 1 week
before the experimental days
• Use of over-the-counter drugs 48
hours before the experimental days
ASA American Society of Anesthesiology (physical status classification system),
BMI body mass index, NRS numerical rating scale, SSRI selective serotonin
reuptake inhibitors
Pereira et al. Trials  (2015) 16:511 Page 3 of 9
placebo in identical 100-ml ampoules. Participants and
investigators will be blinded to the administered infu-
sions. Two copies of the randomization code for each
participant are stored in a secure place, each in a sealed
opaque envelope. One of the envelopes is placed in the
Trial Master File of the study, while the other one is
placed in the examination laboratory, to be opened only
in case of a medical emergency.
Intervention
Participants will be continuously monitored with electro-
cardiography, and, measurements of pulse oximetry, non-
invasive blood pressure, heart rate and respiratory rate,
beginning 25 minutes prior to the infusion (−25 minutes)
and, if no adverse effects are observed, ending 25 minutes
after termination of the infusion (100 minutes). Solutions
of naloxone and placebo will be administered according to
the randomization procedure and are identical in regard
to color, density, transparency and odor.
The TCI-algorithm was calculated by the software NON-
MEM (7.3 ICON Development Solutions, Manchester, UK
(property of University of California, San Francisco (UCSF),
CA, USA)), using computer simulations based on a
population-kinetic model with 2000 simulated administra-
tions distributed on 10 subjects [26]. Thus, a total dose of
3.25 mg/kg of naloxone will be administered in a 3-step ap-
proach (Step 1: 0 minutes to 25 minutes; Step 2: 25 minutes
to 50 minutes; Step 3: 50 minutes to 75 minutes, Fig. 2) as
follows: in the first minute (0–1 minutes) a bolus of
0.02 mg/kg is given followed by an infusion of 0.23
mg/kg during 24 minutes (1–25 minutes). Afterwards
(25–26 minutes) a bolus of 0.06 mg/kg is adminis-
tered followed by a 24-minute infusion of 0.69 mg/kg
(minutes 26–50). Finally, a bolus of 0.18 mg/kg (50–51
minutes) is given followed by a 24-minute infusion of 2.07
mg/kg (51–75 minutes; Table 2). A period of observation
then follows (75 minutes to 180 minutes), after which par-
ticipants are discharged. With this infusion-algorithm, es-
timated naloxone plasma concentrations (median (95 %
confidence interval (CI))) of 344 ng/ml (130;567),
1059 ng/ml (400;1752) and 3196 ng/ml (1205;5276) at
time intervals 15–25 minutes, 40–50 minutes and
65–75 minutes, respectively, are achieved (Fig. 2). An
identical infusion-algorithm is used for the placebo
Fig. 1 Study algorithm. The first experimental day (Day 1) will be performed 6–8 weeks following unilateral, primary, open groin hernia repair and
will be separated by 7 days from the second experimental day (Day 2). Prior to the surgery, patients will receive oral and written information
about the study. A follow-up phone call will be performed 2–3 weeks after surgery to assess the post-surgical pain level and eventual post-surgical
complications. HADS, Hospital Anxiety and Depression Scale; PCS, Pain Catastrophizing Scale
Fig. 2 Day 1/2 test-algorithm with superimposed naloxone plasma-
concentration curves. Mean plasma-concentration (red) with 95 % CI
(dashed black lines) during a 3-step target-controlled infusion. Naloxone
is given at Step 1 with 0.25 mg/kg, Step 2 0.75 mg/kg and Step 3 2.25
mg/kg. Yellow timeline columns represent ratings with Clinical Opiate
Withdrawal Scale (COWS) and blue columns indicate sensory testing
(pain during rest, movement and 100 kPa pressure; pressure algometry;
secondary hyperalgesia area). BL, baseline assessments (−20 minutes
to −8 minutes); S1, Step 1 assessments (15 minutes to 25 minutes); S2,
Step 2 assessments (39 minutes to 49 minutes); S3, Step 3 assessments
(65 minutes to 75 minutes)
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infusion. All outcomes are assessed at baseline (−20
minutes to −8 minutes, Fig. 2) and during infusions
(15 minutes to 25 minutes; 39 minutes to 49 minutes;
65 minutes to 75 minutes, Fig. 2).
Infusions will be discontinued, if participants’ pain
ratings at rest ≥ 5 assessed by the numerical rating
scale (NRS, 0–10). If necessary, analgesic given intra-
venously as rescue medication (alfentanil) will be
given in a titrated fashion for acute pain relief. Other
significant adverse effects that may occur will also be
treated accordingly. Participants will be contacted by
phone the day after each examination day to check
up on potential side effects. All side effects will be re-
corded and reported to the Regional Committee of
Research Ethics and the Danish Health and Medicines
Authority.
Primary outcome
Participants are asked to rate pain intensity (NRS) at
baseline (−20 minutes to −8 minutes, Fig. 2) and during
infusions (15 minutes to 25 minutes; 39 minutes to 49
minutes; 65 minutes to 75 minutes, Fig. 2) using 3 differ-
ent standardized testing-conditions: (1) at rest in the su-
pine position, (2) during transition from supine to
standing position and (3) during a pressure stimulus
(100 kPa) manually applied, perpendicularly at the skin
at the point of maximum pain in the groin (superficial
inguinal ring), using an electronic pressure algometer
(Algometer, Somedic AB, Hörby, Sweden) with a 1-cm2
felt-tipped probe. The summated pain intensity (SPI) is
calculated by adding the NRS scores recorded in the
three conditions. The primary outcome is the difference
in SPI (SPID) at baseline and after infusion of naloxone:
SPIDNx ¼ TCI‐SPINx½   BL‐SPINx½ ; compared to placebo :
SPIDPL ¼ TCI‐SPIPL½   BL‐SPIPL½ ;
(BL, baseline; Nx, naloxone, PL, placebo; TCI, during
target-controlled infusion). The baseline SPI-score
(summated NRS score) will be subtracted from the SPI-
score (summated NRS score), recorded at the highest
obtainable TCI step.
Secondary outcomes
Assessments are performed at the surgical site and at
the mirror-site in the contralateral groin (Fig. 3) at base-
line (−20 minutes to −8 minutes, Fig. 2) and during infu-
sions (15 minutes to 25 minutes; 39 minutes to 49
minutes; 65 minutes to 75 minutes; Fig. 2).
Secondary hyperalgesia/Allodynia
Secondary hyperalgesia and allodynia will be assessed using
a weighted-pin instrument (MRC Systems, Heidelberg,
Germany; 512 mN (10,424 kPa)) and a cotton wool bud, re-
spectively. These assessments will be performed at baseline
(−20 minutes to −8 minutes, Fig. 2) and during infusions
(15 minutes to 25 minutes; 39 minutes to 49 minutes; 65
minutes to 75 minutes, Fig. 2) at the surgical site and at the
mirror-site in the contralateral groin. The border of the
hyperalgesic/allodynic area is determined by stimulating in
8 symmetric lines each separated by an angle of 45° conver-
ging towards the superficial inguinal ring. The stimulations
start in normal skin outside the area of secondary hyper-
algesia/allodynia and participants, with their eyes closed,
are instructed to report a definite change in perception to
an uncomfortable, burning or stinging sensation. The cor-
ners of the octagon are marked on the skin and transferred
to a transparent, acetate sheet. The area is calculated using
a vector-based drawing program (Canvas 12.0, ACD
Systems International, Victoria, BC, Canada). Baseline
outcome values of secondary hyperalgesia area/allodynia
area will be subtracted from the scores of secondary
hyperalgesia/allodynia area assessed at the highest obtain-
able TCI-step.
Pressure pain thresholds
PPT will be assessed using the electronic pressure alg-
ometer applied perpendicularly to the skin with succes-
sively increasing pressure at a rate of 1–2 kPa/s. PPT
assessments will be performed at baseline (−20 minutes
to −8 minutes, Fig. 2) and during infusions (15 minutes
to 25 minutes; 39 minutes to 49 minutes; 65 minutes to
75 minutes, Fig. 2) at the surgical site and at the mirror-
site in the contralateral groin. The assessments will in-
clude the point of maximum pain. Participants interrupt
the stimulation by pushing a button when the pressure
becomes painful. The cut-off value is 350 kPa. Values
exceeding the cut-off are designated 351 kPa. Baseline
outcome values of PPT will be subtracted from the
scores of PPT assessed at the highest obtainable TCI-
step.










Bolus 1 0–1 0.02 1.40 0.35 0.35
Infusion 1 1–25 0.23 16.10 4.03 0.17
Bolus 2 25–26 0.06 4.20 1.05 1.05
Infusion 2 26–50 0.69 48.30 12.08 0.50
Bolus 3 50–51 0.18 12.60 3.15 3.15
Infusion 3 51–75 2.07 144.90 36.23 1.51
TOTAL 3.25 227.50 56.88
Timeline, dose/kg, dose/70 kg, volume/70 kg and infusion rates/min/70 kg for
the 3 step target-controlledinfusion. The total naloxone-dose administered is
227.5 mg per 70 kg BW. The total naloxone volume is 56.9 ml per 70 kg BW.
BW: body weight (kg)
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Assessment of opioid withdrawal symptoms
Signs of opioid-withdrawal will be evaluated using the
examiner-based Clinical Opiate Withdrawal Scale (COWS)
[27] at the beginning of each experimental day and during
infusions (13 minutes to 15 minutes; 37 minutes to 39 mi-
nutes; 63 minutes to 65 minutes, Fig. 2).
Psychometric evaluation
At the beginning of Day 1, participants are asked to fill
out the HADS and the PCS for psychometric
evaluation.
Sample size calculation
The sample size calculation is based on the primary
outcome: SPID before (−20 minutes to −8 minutes,
Fig. 2) and during infusions (15 minutes to 25 minutes; 39
minutes to 49 minutes; 65 minutes to 75 minutes, Fig. 2)
of naloxone:
SPIDNx ¼ TCI‐SPINx½  – BL‐SPINx½ ; compared to placebo :
SPIDPL ¼ TCI‐SPIPL½  – BL‐SPIPL½ ;
where TCI-SPI indicates the summated measure at the
highest obtainable TCI-step. (BL, baseline; Nx, naloxone,
PL, placebo; TCI, during target-controlled infusion).
The sample size calculation is based on a minimal
relevant SPID-difference of 3 NRS-units, a significance
level of 0.01 (α) and a power of 0.9 (β = 0.1). Since no
past studies with similar design and hypothesis have
been performed to support our assumptions, we opted
for this calculation to use an assumed estimate of intra-
individual standard deviation of mean BL-SPI of 1.2
NRS-units. Assuming normal data distribution and a
crossover design, the estimated number of subjects
needed is 9. We plan to include 16 subjects to compen-
sate for eventual dropouts. If the assumed estimate of
intra-individual standard variation is larger than ex-
pected: i.e., 1.7 or 2.5 NRS-units vis-à-vis 1.2 NRS-units,
the corresponding sample size would increase from 9,
to, 14 or 20, respectively (P < 0.01, power = 0.90).
Statistics
To test if data are normally distributed, residual plots
and the Kolmogorov-Smirnov test will be used (SPSS
20.0, Chicago, IL, USA, MedCalc Software: version
12.07.0.0; Mariakerke, Belgium). In case of non-normal
Fig. 3 Examination areas. The examination areas exemplified with a subject after left-sided groin hernia repair. The shaded area, circumscribing
the scar and delineated by sensory testing with a weighted-pin instrument (red crosses), represents a secondary hyperalgesia area. The maximum
pain (red circle) is located above the left superficial inguinal ring. PT (blue circles), pubic tubercle; SIAS (blue circles), superior, inferior iliac spine
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distribution, primarily, logarithmic transformation is
tried or secondarily, a Box-Cox transformation will be
attempted for normalization of the data.
The primary outcome ΔSPID (SPIDNX − SPIDPL) is an-
alyzed by one-way repeated measures ANOVA (ΔSPID:
dependent variable; TCI-steps: independent variable) or
a corresponding non-parametric analogue (Friedman
test), as appropriate. Paired t test or Wilcoxon rank sum
test will be used, as appropriate, for inter-group compar-
isons. A mixed model with random effect for subject
and fixed-effects for the factors: target-controlled infu-
sion (Step 1/Step 2/Step 3), secondary areas of hyper-
algesia, PPT, HADS-scores and PCS-scores, is used for
the primary outcome ΔSPID (SPIDNX – SPIDPL). Non-
significant factors (P > 0.05), beginning with interactions,
are excluded until all included factors attain significance.
Main-effects and interaction-effects are examined.
The risk of type I error is reduced by setting a signifi-
cance level of 0.01 (α). A power of 0.9 (β = 0.1) was
chosen to reduce the risk of type II errors. For all statis-
tical calculations, in which multiple comparisons are
performed, Duncan’s new multiple range test or Scheffé’s
method, as appropriate, will be used. Statistical calcula-
tions will be performed with partially un-blinded data:
i.e., groups A and B. Parametric data will be given as
mean (95 % CI), while non-parametric data will be pre-
sented as median (95 % CI).
Study management
The study will be conducted in accordance with the
guidelines and rules concerning quality control and
quality management on clinical trials involving humans,
and will follow the Good Clinical Practice and the Good
Manufacturing Practice guidelines. All data about poten-
tial and enrolled participants will be treated confiden-
tially. Only the investigators and relevant authorities will
have access to the data. Eventual amendments to the
protocol will be communicated to the relevant author-
ities and the entries on the registry databases will be up-
dated. Positive negative or inconclusive results will be
sought published. The study is registered in EUDRACT
(2015-000793-36) and at the international database
clinicaltrials.gov (NCT01992146).
Discussion
Recent animal studies performed after resolution of in-
flammatory pain showed reinstatement of tactile hyper-
sensitivity following administration of MOR-antagonists,
suggesting latent sensitization mediated by endogenous
opioids [6, 7], serving as a protective mechanism [15–17].
The aim of this study is to show, in humans, latent
sensitization mediated by the endogenous opioid system
in a clinical scenario.
Regarding the naloxone dose, a positron emission
tomography (PET) study from 1989 indicated complete
inhibition of [11C]-carfentanil binding to MOR following
administration of 0.1 mg/kg naloxone [28] in human
volunteers. The present authors are not aware of other
studies replicating these data with newer technologies.
However, a total dose of 3.25 mg/kg of naloxone, which
is 32.5 times higher than the estimated MOR-blocking
dose, and additionally, approximately 500 to 5000 times
higher than the clinical dose used in the treatment of an
opioid overdose [29], will be administered in this study.
The reason for selecting the high dose of naloxone was
twofold. First, by back-translating the human burn-
injury model to rodents, following administration of high
doses of naloxone (3.0 and 10.0 mg/kg), but not low doses
(0.03 and 0.3 mg/kg), we observed signs of late reinstate-
ment of hypersensitivity 21 days after an inflammatory in-
jury [11]. Second, a low-dose naloxone infusion (0.021
mg/kg) [10] did not reinstate secondary hyperalgesia
following resolution of a first-degree burn-injury,
while a high dose (2 mg/kg) induced reinstatement in
4 out of 12 volunteers [11]. Thus, our translational
data from rodents indicate that a high naloxone dose
too is necessary to induce late reinstatement of
hypersensitivity in humans. We attempt in the present
study, to reinstate pain at three gradually increasing, but
stable plasma concentration levels of naloxone, expecting
in this way to obtain a pain reinstatement dose-response
curve.
Concerning the risk of adverse effects induced by ad-
ministration of a high-dose naloxone infusion, we expect
to observe only mild and transient effects. In the transla-
tional study, 2 mg/kg of naloxone was administered to 3
pilot volunteers and 12 study volunteers. Six volunteers
reported mild transient adverse effects, including tired-
ness, epigastralgia, frontal headache and photophobia.
Furthermore, naloxone did not induce any overt changes
in electrocardiography, blood pressure, heart and re-
spiratory rate and oxygen saturation during the experi-
mental days [11]. Additionally, doses up to 6 mg/kg have
been used parenterally in previous studies both in
healthy volunteers [18–22, 30] and in patients [31–36],
and, only mild to moderate transient adverse effects have
been recorded. We are, therefore, confident that the risk
of development of complications or serious adverse reac-
tions associated with the administration of a total nalox-
one dose of 3.25 mg/kg is highly unlikely. Moreover, in
the present study we are using TCI to increase the na-
loxone plasma concentration step-wise, allowing blood-
brain equilibrium to be obtained. Since the estimated
steady-state conditions are obtained in less than 15 mi-
nutes [37], the adverse reactions can, therefore, be de-
tected much earlier and at a lower naloxone dosage,
compared with a single-bolus-based regimen.
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In regard to the risk of development of a sustained
pain state after the naloxone administration in patients
after GHR, we consider it highly unlikely. Naloxone is a
short-acting reversible antagonist of opioid receptors
and does not affect the production of endogenous opi-
oids. Moreover, a prolonged reversal of endogenous opi-
oids is unlikely due to the pharmacokinetic properties of
naloxone. In adults, the distribution half-life of naloxone
is 40 to 70 seconds [38], and the elimination half-life, 54
to 64 minutes [38, 39] and no known, active long-acting
metabolites are formed. Furthermore, in the previously
mentioned rodent study [7], administration of naltrex-
one or naloxone led to transient episodes of hypersensi-
tivity with duration of 60 to 90 minutes, while repeated
administration of naltrexone, over the course of months,
has confirmed full reversibility of the hypersensitivity ep-
isodes. In addition, our data from the high-dose nalox-
one (2 mg/kg) study in volunteers only indicated very
short lasting changes in hypersensitivity [11].
The experimental days are taking place 6–8 weeks
after surgery, time-points at which patients are nearly
pain-free, albeit before the surgically induced tissue in-
jury has fully resolved. Our primary outcome is a sum-
mated measure of reinstatement of pain (at rest, during
transition from supine to standing position and evoked
by pressure algometry), since pain is the most relevant
outcome in the clinical setting. For the sample size cal-
culation we opted to use a minimal relevant difference
of 3 NRS-units, which is relatively low, considering our use
of a summated measure (SPI) of 3 assessments (resting
pain, movement-related pain and pressure evoked pain).
Baseline SPI is estimated to be 8 (mean per assessment =
2.7) NRS-units: a significant increase would then be ≥ 11
(mean per assessment ≥ 3.7) NRS-units: i.e., ≥ 38 %.
Additionally, secondary outcomes (secondary hyper-
algesia/allodynia and PPT), which are of exploratory na-
ture, will provide information on sensory properties of
the surgical site and of the mirror-site in the contralat-
eral groin, and how they are modulated by naloxone.
Since secondary hyperalgesia is a measure of central
sensitization, it is of interest to differentiate between
subjects developing large secondary areas of hyperalgesia
(high-sensitizers) and subjects developing small areas
(low-sensitizers). Past research has shown that the size
of the secondary area of hyperalgesia is reproducible
within subjects and can thus be regarded as a phenotype
[40]. It is unclear whether different sensitization phenotypes
have varying susceptibility to develop latent sensitization.
Interestingly, data from the translational study indicated
that volunteers showing reinstatement of secondary hyper-
algesia by naloxone administration exhibited significantly
larger baseline areas of secondary hyperalgesia compared to
naloxone non-responders. However, due to the small num-
ber of volunteers showing reinstatement (n = 4) cautious
interpretation is required [11]. This is in agreement with
the study by Corder et al., which used strain C57BL/6 ro-
dents [7], known to have enhanced sensitivity to pain [41,
42]. In the present study, the magnitude of the secondary
area of hyperalgesia at the surgical site will be correlated
with the magnitude of pain reinstatement (SPID). This may
thus provide important insights on whether a specific
subgroup of subjects is more predisposed to latent
sensitization.
In conclusion, by administrating a high-dose TCI of na-
loxone, the present study aims to show dose-dependent
reinstatement of pain and hyperalgesia following recovery
from a unilateral, primary, open GHR procedure. This
would provide further evidence of opioid- mediated latent
sensitization in humans. We consider that impairment of
the protective endogenous opioid system may play a rele-
vant role in the development of persistent post-surgical
[43] or post-traumatic pain: thus, the long-term goal of al-
leviating persisting pain should be focused either at facili-
tating the endogenous opioid analgesia, restricting latent
sensitization within a state of remission, or at measures
that more effectively suppress latent sensitization [5].
Trial status
Inclusion of the first participants is expected in fall 2015.
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